Yet another interesting article, just published June 30, 2022, from another board.

"In the need of reinforcing the drug repositioning strategy
and developing specific SARS-CoV-2 treatment, recently,
three main groups of scientists discovered that a new
antibacterial drug, named brilacidin, provides attractive
benefits against SARS-CoV-2, and specifically without
major side effects.
This previous findings were confirmed by Xu, et al. [2],
who further, specified that the protective effect of brilacidin
is more likely to be preventive than curative, as brilacidin
has no inhibition/protective effect after SARS-CoV-2-cell
attachment, but only can inhibit SARS-CoV-2 entry into
cells.
Furthermore, while Xu, et al. [2] demonstrated the
effectiveness of brilacidin against SARS-CoV-2 and its
derivative variants including P.1 and B.1.1.7 strains, Hu, et
al. [3] discovered that brilacidin protective activity has a
broader spectrum to other sarbecoviruses, including OC43,
229E, and NL63 strains.
Highlights
1. Brilacidin protects cells from SARS-Co-2 infection,
at low dose.
2. Brilacidin has a broad-spectrum antiviral activity
against multiple Human Coronaviruses (HCoVs)
including SARS-CoV-2 and its derivatives, HCoV-
229E, HCoV-OC43, and HCoV-NL63.
3. Brilacidin has a dual antiviral mechanism of
action, including virucidal activity and binding to
coronavirus attachment factor HSPGs on the host
cell surface.

https://www.jelsciences.com/articles/jbres1504.pdf